What is it about?
This review is about microbial living therapeutics (MLTs), an emerging class of programmable drug-delivery systems in which engineered microorganisms, particularly genetically modified bacteria and probiotic platforms, function as living therapeutic agents. It explains how these systems combine synthetic biology, genetic circuits, biosensing, immunomodulation, and advanced formulation technologies to sense specific disease-associated microenvironments and produce or release therapeutic molecules directly at the site of disease. The review covers applications across cancer, autoimmune and inflammatory diseases, metabolic disorders, neuro-immunological conditions, infectious diseases, and rare genetic disorders, while also discussing advances in microbial chassis engineering, biocontainment, encapsulation, biomaterial–microbe hybrids, and stimuli-responsive delivery. Importantly, it addresses the major challenges limiting clinical translation, including microbial viability, biodistribution, safety, controlled activation, manufacturing, and quality control, and highlights how microbiome profiling, multi-omics, and computational modeling could enable better patient stratification and therapeutic predictability. Overall, the review presents engineered microbes as programmable biological medicines capable of adaptive, localized, and sustained therapeutic delivery, with significant potential for precision medicine.
Featured Image
Photo by CDC on Unsplash
Why is it important?
This review is important because it highlights a fundamental shift in drug delivery from static therapeutic molecules toward programmable living systems capable of sensing, responding, and adapting to disease-associated microenvironments. By focusing on engineered microbial living therapeutics, it demonstrates how synthetic biology can transform microorganisms into controllable therapeutic factories that provide localized, sustained, and context-dependent delivery of drugs and biological payloads. The integration of biosensing, genetic circuits, immunomodulation, microbial engineering, and advanced formulations offers solutions to major limitations of conventional therapies, particularly poor targeting, systemic toxicity, and inadequate control over drug exposure. Importantly, the review also connects recent advances in biocontainment, formulation, multi-omics, microbiome profiling, and computational modeling with the growing clinical translation of these platforms, positioning microbial living therapeutics as a promising foundation for safer, more precise, and adaptive next-generation medicines.
Perspectives
From my perspective, microbial living therapeutics represent a significant evolution in drug delivery because they transform microorganisms from passive carriers into programmable, responsive therapeutic systems. I find the ability of engineered microbes to sense disease-specific microenvironments, regulate gene expression, and produce therapeutic payloads in situ particularly compelling, as it offers the possibility of achieving localized and sustained treatment while minimizing systemic exposure. The convergence of synthetic biology, immunomodulation, microbial engineering, and advanced formulation technologies further expands their therapeutic versatility across cancer, inflammatory, metabolic, infectious, and neuro-immunological diseases. In my view, the most important future opportunity lies in integrating these living platforms with microbiome profiling, multi-omics, computational modeling, and precision medicine to achieve patient-specific therapeutic responses. At the same time, rigorous attention to biosafety, biocontainment, biodistribution, manufacturing, and regulatory standardization will be essential for translating this promising technology from experimental systems into clinically reliable biological medicines.
Mr Lahanya Guha
Read the Original
This page is a summary of: Living drug carriers: Microbial and bioengineered platforms redefining precision therapeutic and immunomodulatory delivery, Journal of Controlled Release, August 2026, Elsevier,
DOI: 10.1016/j.jconrel.2026.115274.
You can read the full text:
Contributors
The following have contributed to this page
